FindTrial
Sign In

A study in healthy adults to evaluate the moisturizing and skin improvement effects of Sebo Clear Body Lotion

An Open-Label, Single-Arm, Interventional Clinical Study to Evaluate the Moisturizing Efficacy, Skin Lightening, Smoothening Effects, Freshness, and Safety of Sebo Clear Body Lotion in Healthy Adult Subjects Over 14 Days - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/109554
Enrollment
34
Registered
2026-04-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Seboclear Body Lotion: Topical body lotion applied twice daily (morning and evening) on the designated body area for 14 consecutive days Control Intervention1: Not Applicable: This is a
no comparator or control group is included

Sponsors

SKINOVATE LASER & COSMETIC SURGERY CENTRE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Healthy male and female subjects aged 18 65 years No active dermatological conditions Subjects with normal to dry skin types Fitzpatrick skin types I IV Willingness to provide written informed consent

Exclusion criteria

Exclusion criteria: Pregnant or breastfeeding women Significant dermatological or systemic conditions affecting skin Active dermatoses on test area Known hypersensitivity to cosmetic products Use of topical/systemic treatments affecting skin within: 2 weeks (topical) 4 weeks (systemic) Participation in another study within 30 days History of substance abuse

Design outcomes

Primary

MeasureTime frame
To assess the moisturizing efficacy of Sebo Clear Body LotionTimepoint: At baseline prior to product application (Day 1) At Day 7 during treatment At Day 14 at end of study—

Secondary

MeasureTime frame
To evaluate skin lightening effect To assess skin smoothening To evaluate freshness perception To assess safety and tolerability via patch test and clinical evaluation Timepoint: 14 Days—

Countries

India

Contacts

Public ContactDr Avinash Bajirao Jadhav

Punawale Multispecialty Hospital

dr.avinashjadhav2@gmail.com07378306651

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026